Sihuan Pharmaceutical Holdings Group Ltd.
0460 · HKEX · Hong Kong
Price data from its TEL1 listing on XSTU, quoted in EUR
sihuanpharm.comFinancials as of FY2025
What stands out
- Earnings significantly exceed cash generation
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $1.58B, above the global median of $1.14B
- FinancialsAltman Z-Score 2.11: grey zone
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
1.54%Below 5Y avg (1.72%)
Annual Rate
HKD 0.01Paid annual
Payout Ratio
58.4%Sustainable
Payback Period
6.7 yr
Last Ex-Dividend
Jun 30, 2026
The reported statements, read against the company's own industry.
What stands out
- Earnings significantly exceed cash generation
Financials view
Market Capitalization
12.36BHKD1.58B · vs all stocks (USD)
Trailing P/E
17.88xRevenue (TTM)
3.09BCNY394.37M · vs all stocks (USD)
Profit Margin
11.46%Beta
0.7960xvs all stocks
52-Week Change
-51.37%vs all stocks
Market Capitalization
12.36BHKD1.58B · vs all stocks (USD)
Enterprise Value
5.48BHKD698.14M · vs all stocks (USD)
Trailing P/E
17.88xForward P/E
-35.75xPrice to Sales (TTM)
2.48xPrice to Book (MRQ)
0.8913xEnterprise to Revenue
1.77xEnterprise to EBITDA
7.04xProfit Margin
11.46%Operating Margin
19.59%Return on Assets (TTM)
2.80%Return on Equity (TTM)
5.58%Revenue (TTM)
3.09BCNY394.37M · vs all stocks (USD)
Revenue per Share (TTM)
0.2920CNYUpdated Oct 22, 2026Quarterly Revenue Growth
1.30%Gross Profit (TTM)
2.03BCNY258.56M · vs all stocks (USD)
EBITDA (TTM)
795.39MCNY101.38M · vs all stocks (USD)
Net Income (TTM)
354.64MCNY45.20M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
119.00%Operating Cash Flow (TTM)
-24.03MCNY-3.06M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-657.96MCNY-83.86M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.0109HKDUpdated Oct 22, 2026Trailing Annual Dividend Yield
1.54%vs all stocks
5-Year Average Dividend Yield
1.72%vs all stocks
Payout Ratio
58.37%Minority Interest (Equity)
1.05BCNYFY2025 · Dec 31, 2025Revenue
2.62BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
816.15MCNYFY2025 · Dec 31, 2025Gross Profit
1.80BCNYFY2025 · Dec 31, 2025Operating Income
375.09MCNY56.22M · vs all stocks (USD)
Pre-tax Income
417.16MCNYFY2025 · Dec 31, 2025Income Tax Expense
231.75MCNYFY2025 · Dec 31, 2025Net Income
185.40MCNYFY2025 · Dec 31, 2025EBIT
618.73MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
795.39MCNYFY2025 · Dec 31, 2025Research & Development
291.27MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
1.12BCNYFY2025 · Dec 31, 2025Other Operating Expenses
46.33MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
98.83MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
201.57MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.0197CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.0197CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
9.12BSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
9.12BSharesFY2025 · Dec 31, 2025Minority Interests (P&L)
-5.71MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-366.56MCNYFY2025 · Dec 31, 2025Free Cash Flow
-383.61MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
3.56BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
417.16MCNYFY2025 · Dec 31, 2025Stock-based Compensation
9.03MCNYFY2025 · Dec 31, 2025Other Non-cash Items
102.75MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-690.78MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-204.72MCNYFY2025 · Dec 31, 2025Capital Expenditures
-17.05MCNYFY2025 · Dec 31, 2025Net Intangibles (CF)
-136.15MCNYFY2025 · Dec 31, 2025Net Acquisitions
31.68MCNYFY2025 · Dec 31, 2025Purchase of Investments
-8.20BCNYFY2025 · Dec 31, 2025Sale of Investments
7.81BCNYFY2025 · Dec 31, 2025Other Investing Activity
-18.15MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-395.44MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
272.41MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-277.95MCNYFY2025 · Dec 31, 2025Common Stock Repurchase
-188.63MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-90.89MCNYFY2025 · Dec 31, 2025Other Financing Charges
706.70MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
421.65MCNYFY2025 · Dec 31, 2025Shares Outstanding
9.04BSharesUpdated Oct 22, 2026Float Shares
3.66BSharesUpdated Oct 22, 2026% Held by Insiders
56.31%vs all stocks
% Held by Institutions
7.67%vs all stocks
Total Cash (MRQ)
4.18BCNY532.89M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.3950CNYUpdated Oct 22, 2026Total Debt (MRQ)
1.15BCNY145.94M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.1400xCurrent Ratio (MRQ)
1.80xBook Value per Share (MRQ)
0.8022CNYUpdated Oct 22, 2026Total Assets
11.63BCNY1.74B · vs all stocks (USD)
Total Current Assets
6.65BCNYFY2025 · Dec 31, 2025Total Liabilities
4.73BCNYFY2025 · Dec 31, 2025Total Non-current Assets
4.98BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
1.04BCNYFY2025 · Dec 31, 2025Total Current Liabilities
3.69BCNYFY2025 · Dec 31, 2025Cash
3.05BCNYFY2025 · Dec 31, 2025Cash Equivalents
511.82MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
3.56BCNYFY2025 · Dec 31, 2025Other Short-term Investments
416.78MCNYFY2025 · Dec 31, 2025Accounts Receivable
1.06BCNYFY2025 · Dec 31, 2025Inventory
617.73MCNYFY2025 · Dec 31, 2025Accounts Payable
387.72MCNYFY2025 · Dec 31, 2025Short-term Debt
272.09MCNYFY2025 · Dec 31, 2025Other Current Liabilities
1.29BCNYFY2025 · Dec 31, 2025Long-term Debt
734.58MCNYFY2025 · Dec 31, 2025Common Stock (Book)
77.06MCNYFY2025 · Dec 31, 2025Retained Earnings
601.75MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
6.90BCNY1.03B · vs all stocks (USD)
Treasury Stock
242.73MCNYFY2025 · Dec 31, 202552-Week Low
0.6850HKDUpdated Oct 22, 202652-Week High
1.79HKDUpdated Oct 22, 202652-Week Change
-51.37%vs all stocks
Beta
0.7960xvs all stocks
50-Day MA
0.7676HKDUpdated Oct 22, 2026200-Day MA
1.11HKDUpdated Oct 22, 2026Avg 10-Day Volume
25.39MSharesUpdated Oct 22, 2026Avg 30-Day Volume
20.88MSharesUpdated Oct 22, 2026Diluted EPS (TTM)
0.0400CNYUpdated Oct 22, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Earnings significantly exceed cash generationSignificant
Net Income (USD, TTM): 45,203,008.746Operating Cash Flow (USD, TTM): -3,062,541.836
Financial Health
Altman Z-Score 2.11: grey zoneSignificant
Altman Z-Score: 2.11
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $1.58B, above the global median of $1.14BNotable
Market cap (USD): 1,575,135,904.709Global Median: 1,137,180,293.291
Companies that share the same coordination system — how they create, deliver, or capture value.
Absci Corporation
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
MeHow Innovative Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Inner Mongolia Furui Medical Science Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Mayinglong Pharmaceutical Group Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tibet Cheezheng Tibetan Medicine Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Yifan Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zhejiang Conba Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai MicroPort Endovascular MedTech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Phibro Animal Health Corporation
Tier 1ProductionApproval-Gated PipelineRule
Consun Pharmaceutical Group Limited
Tier 1ProductionApproval-Gated PipelineRule